The MOH Singapore capitation commitment under Healthier SG -- 1.2 million enrolled residents as of Q1 2026, S$1.1 billion budgeted across the 2023-2027 spending horizon -- is pricing a population-level shift from episodic acute care to enrolled preventive management. The enrolled chronic disease protocols driving that spend (HbA1c monitoring for Type 2 diabetes, lipid panels at 24-month intervals, colorectal cancer screening via FIT at ages 50-75) draw on WHO WPRO guidance and local registry data from the MOH Health Promotion Board, not on randomised controlled trial evidence specific to the Singaporean multi-ethnic population; the Tamil and Malay subgroup data on HbA1c thresholds, specifically, remain extrapolated from trials powered on Han Chinese and European cohorts.

The gap between enrolled scale and validated protocol is not a scandal. It is the architecture: Singapore's Agency for Integrated Care is building the delivery infrastructure now, before the subgroup-specific RCT evidence exists, on the reasonable bet that a enrolled-GP capitation model produces better chronic disease outcomes than fee-for-service episodic care even with imperfect protocols. My read is that bet is probably correct on the direction and probably overconfident on the timeline -- the first five-year outcome cohort from the Healthier SG registry will not be large enough for meaningful subgroup analysis before 2029, which means the S$1.1 billion capital commitment will be substantially deployed before MOH's own Centre for Quantitative Medicine can validate the protocols it was built to deliver.